Merck, P&G and Other Dividend Stocks You Wish You'd Bought in 2013
at The Street - 44 mins ago
I've covered these dividend winners before, but you're not too late to get on board.
Will These 3 Dividend Stocks Impress Investors This Earnings Season?
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 23, 5:30PM CDT
Earnings season already has produced its fair share of surprises, but big pharma's hardly even broken out of the gate so far. However, a trio of major drugmakers are set to release their quarterly results in the next two weeks, and all eyes in the...
Andrzej S. Krolewski, MD, PhD, Receives American Diabetes Association's Kelly West Award for Outstanding Achievement in Epidemiology
Marketwire - Wed Apr 23, 12:13PM CDT
The American Diabetes Association will present the Kelly West Award for Outstanding Achievement in Epidemiology to Andrzej S. Krolewski, MD, PhD. Supported by an unrestricted educational grant from Merck, this award is given to an individual who has made significant contributions to the field of diabetes epidemiology. Dr. Krolewski will be recognized with this honor at the Association's 74th Scientific Sessions(R), taking place June 13-17, 2014, at the Moscone Center in San Francisco.
Edward S. Horton, MD, Receives American Diabetes Association's Albert Renold Award
Marketwire - Wed Apr 23, 12:12PM CDT
The American Diabetes Association will present the Albert Renold Award to Edward S. Horton, MD. Supported by a grant from Merck, this award is presented to an individual whose career is distinguished by outstanding achievements in the training and mentorship of diabetes research scientists and in the facilitation of diabetes research. Dr. Horton will be recognized with this honor at the Association's 74th Scientific Sessions(R), taking place June 13-17, 2014, at the Moscone Center in San Francisco.
Gilead, Illumina Q1 Earnings Win Wall Street's Love
at Investor's Business Daily - Wed Apr 23, 10:39AM CDT
Analysts were singing the praises of life-science giants Gilead Sciences (GILD) and Illumina (ILMN) Wednesday morning after both surged above Q1 estimates late Tuesday. Shares of both companies were up on the stock market today. Gilead's $2.3 billion...
Stock Market News for April 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Apr 23, 9:06AM CDT
Benchmarks ended higher on Tuesday boosted by better-than-expected corporate results
Say Hello to the New Fastest Growing Drug in History!
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 23, 9:03AM CDT
Take every guess you had as to how well Gilead Sciences would perform in the first-quarter, no matter how outrageous, and completely throw them out the window because Gilead would have trumped it! Break out your thesaurus because you'll need...
Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals
PR Newswire - Wed Apr 23, 7:00AM CDT
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it is teaming up with Emmy and Golden Globe-winning actress S. Epatha Merkerson on America's Diabetes Challenge: Get to Your Goals, an educational program intended to encourage people with type 2 diabetes to achieve better control of their blood sugar -- a key goal to help reduce the risk of serious health problems. Merkerson, who lives with type 2 diabetes, will travel the country urging people to know their A1C (average blood sugar level over the past two to three months) and to work with their doctors to set and attain their own A1C goal.
Merck KGaA: Form 8 (DD) - AZ Electronic Materials S.A.
Marketwire - Wed Apr 23, 6:37AM CDT
Merck KGaA (FRANKFURT: MRK)
The COPD Drug Market Opportunity & Clinical Pipeline Analysis 2014-2018
M2 - Wed Apr 23, 3:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4stq5l/copd_drug_market) has announced the addition of the "COPD Drug Market Opportunity & Clinical Pipeline Analysis" report to their offering. The market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018 Close to 1 Billion people worldwide suffer from respiratory or pulmonary diseases. In the respiratory therapeutic domain, Asthma and COPD are the major categories, accounting for close to 75% of the total patient for respiratory or pulmonary diseases. Chronic obstructive pulmonary disease (COPD) is a disease which progresses in the lungs and requires treatment all through the life. It is an inflammatory disorder which is characterized by obstruction in the variable airflow and airway hyper-responsiveness to many intrinsic, genetic and environmental stimuli. These disorders have become one of the major reasons for disability and death. The prevalence and incidence of this disease is increasing worldwide. Bronchodilators and polypharmacy dominates the treatment for this disease. It is expected that by 2020, COPD would account for more than 6 Million deaths across the globe annually. Inspite of significant investments in the development of novel agents to treat the disease, the COPD therapy area is generally dominated by inhaled bronchodilator therapies which only relieve symptoms, but do not completely cure the disease. There exist many opportunities for a disease-modifying therapy. However, the development of new COPD therapies is increasingly focusing on therapies which combine two bronchodilators into one inhaler. There has been significant expansion in the COPD drug market in the recent years and it is expected that this market would record high growth over the next decade. The major driving force in the future would be a greater demand for new drugs with higher and better efficiency. This market has been recognized to be one with many opportunities which are yet to be tapped. Hence, the leading pharma companies are increasing their focus on this segment by introducing new combination drugs and novel agents. The global market for COPD has been estimated to be close to US$ 12 billion in 2013. With a high number of new and more efficient and convenient drugs crowding the market, it is expected that this market would grow at a CAGR of 8% to reach close to US$ 17.5 billion by 2018. Key Topics Covered: 1. Global Chronic Obstructive Pulmonary Disease Market Overview 2. EMA Guideline on Clinical Investigation of COPD Drugs 3. FDA Guideline on Clinical Investigation of COPD Drugs 4. Chronic Obstructive Pulmonary Disease Drug Clinical Trial by Phase & Country 5. Marketed Drugs for Chronic Obstructive Pulmonary Disease by Country 6. No Development, Discontinued & Suspended Drug Clinical Trial by Phase & Country 7. Competitive Landscape - Almirall - AstraZeneca, - Bayer - Boehringer Ingelheim, - Chiesi Farmaceutici - Forest Laboratories - Lallemand Pharma - Merck & Co - Novartis - Sunovion Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/4s...rug_market
Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019
M2 - Wed Apr 23, 2:31AM CDT
Research and Markets (http://www.researchandmarkets.com/research/35ctmw/hepatitis_c) has announced the addition of the "Global Hepatitis C Therapeutics in Major Developed Markets 2013-2019" report to their offering. The global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Products with these mechanisms of action have performed strongly in the commercial setting, with the market leader Incivek (a DAA) having reached blockbuster sales. However, these products are very poorly tolerated and only moderately efficacious. The approval of the DAA Sovaldi in December 2013 changed this, with a complete viral clearance being achieved in close to 100% of patients and a much improved adverse event profile compared to previous standards of therapy. In patients with genotype 2 and 3 hepatitis C, Sovaldi does not need to be administered with pegylated interferon. A number of products in the late-stage pipeline, which promise to be even more efficacious and safe are anticipated to enter the market over the forecast period, including several interferon-free therapies for genotype 1-infected patients. As a result of this, as well as an overall increase in the treated population, the authors believe the global market has the potential to grow to a value of $18.6 billion by 2019, more than tripling the 2012 market value of $5.8 billion. Scope - A brief introduction to hepatitis C, including the disease's pathogenesis, risk factors and diagnosis, and detailed analyses of disease epidemiology and treatment algorithms. - In-depth analysis of the major antiviral drugs used in the treatment of hepatitis C, including analyses of their safety, efficacy, treatment patterns and strengths/weaknesses. Includes a heat map that compares marketed drugs in terms of safety and efficacy. - A comprehensive review of the pipeline for hepatitis C therapies, including individual analysis of a number of late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed by phase distribution, molecule type and molecular target. - In-depth clinical trial enrolment, trial duration and program failure rate analyses for each molecule type and mechanism of action. Additionally, clinical trial endpoints and certain selection criteria are analyzed in great depth. This section also includes an additional heat map regarding pipeline products, and a direct cross-analysis against currently marketed products. - Multi-scenario forecast data of the market to 2019, which takes into account the effects of the introduction of new drugs, the expiry of key patents on current drugs and the changes in disease epidemiology across the key developed markets: US, Canada, Japan, Germany, UK, France, Italy and Spain. - Discussion of the drivers and barriers for market growth. - Analysis of licensing and co-development deals occurring in the hepatitis C market. Key Topics Covered: 1 Tables & Figures 2 Introduction - Signs and Symptoms - Etiology and Risk Factors - Pathophysiology - Epidemiology - Prognosis - Treatment 3 Marketed Products - Ribavirin - Pegasys (Peginterferon alfa 2a) and PegIntron (Peginterferon alfa 2b) - Hoffmann La Roche and Merck & Co - Incivek (telaprevir) - Vertex Pharmaceuticals and Janssen-Cilag - Victrelis (boceprevir) - Merck & Co - Olysio (simeprevir) - Johnson and Johnson - Sovaldi (sofosbuvir) - Gilead Sciences - Heat Map for Marketed Products 4 Developmental Pipeline - Overall Pipeline - Mechanisms of Action - Clinical Trials - Promising Pipeline Drugs - Heat Map and Competitor Matrix for Pipeline Products - Conclusion 5 Market Forecast to 2019 6 Drivers and Barriers 7 Licensing and Co-development deals 8 Appendix For more information visit http://www.researchandmarkets.com/research/35...epatitis_c
Asia shares mixed on lackluster China data
By ELAINE KURTENBACH - AP - Tue Apr 22, 11:08PM CDT
TOKYO (AP) — Shares were mixed in Asia on Wednesday, as weak data from China sapped upward momentum from an overnight rally on a flurry of deals in the pharmaceutical sector.
Valeant, Ackman make $45.6B Allergan bid
AP - Tue Apr 22, 7:43PM CDT
NEW YORK (AP) — Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.
Drugmakers Prod European Stocks To Post-Easter Rally
at Investor's Business Daily - Tue Apr 22, 5:36PM CDT
European exchanges were high scorers on the world map Tuesday, as investors returned with vigor from the four-day holiday. Germany's Frankfurt Exchange led the pack, with the DAX index vaulting 2% higher. In Italy, Milano's FTSE MIB punched up 1.5%....
A Doozy of a Pharma Rumor
Brian Orelli, The Motley Fool - Motley Fool - Tue Apr 22, 5:30PM CDT
The latest health care acquisition rumor is a doozy. According to multiple news outlets, Pfizer was in talks with AstraZeneca to acquire the company for over $100 billion, although the companies apparently broke off talks. Interestingly, this...
Novartis, Glaxo Swap Units; Lilly Buying Animal Biz
at Investor's Business Daily - Tue Apr 22, 10:49AM CDT
Big pharmas Novartis (NVS), GlaxoSmithKline (GSK) and Eli Lilly (LLY) announced a massive exchange of business units Tuesday morning in a set of deals with a total value of more than $28 billion. Novartis and Glaxo rose on the stock market today,...
Next Resistance Level for Merck (MRK) is $57.88
Comtex SmarTrend(R) - Tue Apr 22, 9:37AM CDT
Shares of Merck (NYSE:MRK) opened today above their pivot of $56.98 and have already reached the first level of resistance at $57.57. Investors may be interested in a cross of the next upside pivot targets of $57.88 and $58.78.
Why Johnson & Johnson Is Outperforming the Dow
George Budwell, The Motley Fool - Motley Fool - Tue Apr 22, 8:30AM CDT
After setting record highs in 2013, the Dow Jones Industrials has largely traded sideways so far in recent months, down just 0.20% in 2014. Given the general weakness among health care stocks of late, you might suspect that pharma companies have...
Global Human Reproductive ((Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) Technologies Market 2013-2019
M2 - Tue Apr 22, 8:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/bcxdpd/human) has announced the addition of the "Human Reproductive Technologies Market - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Reproductive technologies are used to treat infertility problems in males as well as in females. Since the last decade, a remarkable prevalence of infertility has been observed worldwide and its morbidity rate is rapidly growing. Changes in lifestyle such as delay in bearing the first child, use of contraceptive pills, increased alcohol consumption and smoking are some of the factors leading to increase in the infertility rate globally, due to which the human reproductive technologies market is experiencing rise in demand. Human reproductive technologies are mainly categorized on the basis of infertility treatments and contraceptive technologies. The infertility drugs market is analyzed based on the big seven brands (by sales) such as, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Viagra, Gonal-f and AndroGel are the major drugs in their respective drug classes, which are preferred majorly for treating different causes of infertility. Further, the human reproductive technologies market is analyzed by various infertility treatment procedures which is led by the intrauterine insemination (IUI) procedure owing to low procedural cost and less complexity in performing the procedure. Contraceptive technologies market is segmented into contraceptive drugs such as oral contraceptive pills, contraceptive injectables and topical contraceptives; and devices such as male and female contraceptive devices. Within the contraceptives market, the market share of male contraceptives was the largest due to factors such as ease of use, lack of side effects and higher availability. The market will be driven by factors such as increase in conception rate, rising prevalence of unwanted pregnancies and sexually transmitted diseases (STDs). The global human reproductive technologies market is highly fragmented in nature with many companies currently competing in the market. Well established market players such as Merck & Co., Inc., Ferring International Center S.A., Pfizer, Inc. Merck Serono and Bayer AG dominate this market with their proprietary products and predatory growth strategies. Patent repositories of the established market players are restraining the entry and growth of new players entering the market. The global human reproductive technologies market is categorized into the following segments: Infertility Drugs - Gonal-f (recombinant follitropin alfa) - Follistim AQ (follitropin beta) - AndroGel (testosterone) - Testim (testosterone) - Viagra (sildenafil citrate) - Cialis (tadalafil) - Levitra/Staxyn (vardenafil) Infertility Procedures - In Vitro Fertilization (IVF) - Intracytoplasmic Sperm Injection (ICSI) - Zygote Intrafallopian Transfer (ZIFT) - Gamete Intrafallopian Transfer (GIFT) - Intrauterine Insemination (IUI) Contraceptive Technologies - Drugs - - Oral Contraceptive Pills - - Contraceptive Injectables - - Topical Contraceptives - Devices - - Male Contraceptive Devices (Male Condoms) - - Female Contraceptive Devices Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Human Reproduction Technologies Market, by Infertility Treatment - Global Human Reproductive Technologies Market, by Contraceptive Technologies - Global Human Reproductive Technologies Market Revenue, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Actavis, Inc. - Bayer AG - Church & Dwight, Co. Inc. - Cook Medical, Inc. - Ferring International Center S.A. - Johnson & Johnson - Merck & Co., Inc. - Merck Serono - Pfizer, Inc. - Reckitt Benckiser Group plc - Teva Pharmaceutical Industries Ltd. - Warner Chilcott plc For more information visit http://www.researchandmarkets.com/research/bcxdpd/human